Preventing Obesity in Preterm Infants

预防早产儿肥胖

• 批准号: 10667416
• 负责人: Catherine O Buck
• 金额: $ 16.68万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667416
• 关键词: 2 year old; Acceleration; Adipose tissue; Adolescence; Adult; Affect; Age; Biological Markers; Biometry; Biostatistical Methods; Birth; Blood Pressure; Body Composition; Body fat; Body mass index; Cardiometabolic Disease; Child; Childhood; Clinical Research; Clinical Trials; Data; Development; Development Plans; Diabetes Mellitus; Dietary Intervention; Endocrinology; Energy Metabolism; Exposure to; Fatty acid glycerol esters; Future; Gestational Age; Gestational Diabetes; Goals; Growth; Growth and Development function; High birth weight infant; Hospitalization; Hospitals; Infant; Intervention; Lead; Leptin; Life; Longitudinal Studies; Magnetic Resonance Imaging; Mentors; Metabolic syndrome; Metabolism; Monitor; Mothers; Newborn Infant; Nutritional; Obesity; Pattern; Perinatal; Perinatal Epidemiology; Perinatal Exposure; Pharmacotherapy; Phenotype; Pregnancy; Premature Birth; Premature Infant; Prospective cohort; Race; Research; Research Design; Research Methodology; Research Personnel; Research Project Grants; Risk; Role; Skinfold Thickness; Tissues; Training; United States; Visceral; Vulnerable Populations; Weight; Weight Gain; Woman; adiponectin; candidate marker; cardiometabolism; career development; cost estimate; critical period; early childhood; early detection biomarkers; epidemiology study; high risk population; hormone metabolism; infant nutrition; insulin sensitivity; maternal diabetes; maternal obesity; newborn adiposity; non-diabetic; obesity development; obesity in children; obesity prevention; obesity risk; offspring; perinatal environment; perinatal period; postnatal; prepregnancy; prevent; prospective; public health relevance; risk stratification; sex; sociodemographic factors; subcutaneous; therapy development

PROJECT SUMMARY The objective of this research project is to determine if indicators of adipose tissue development and metabolism are candidate biomarkers to identify preterm infants at risk of childhood obesity and cardiometabolic abnormalities. Infants born moderately preterm, between 32- and 36-weeks of gestational age, have 20% higher odds of obesity and cardiometabolic disease in adulthood compared with those born at term. Moderate preterm birth accounts for 8% of all births, or approximately 300,000 children born in the United States each year. Factors that may contribute to obesity risk among preterm infants include developmental re- programming due to perinatal exposure to maternal obesity and diabetes. Preliminary data shows that moderate preterm infants of mothers with diabetes have greater in-hospital growth over an average of 9 days compared with infants of non-diabetic mothers, after adjustment for gestational age, sex, and race. Accelerated growth in these infants may be due to alterations in the development, metabolism, and localization of adipose tissue. In a prospective cohort of moderately preterm infants, the aims of this project are: To determine the effect of maternal obesity and gestational diabetes on the development of adiposity at term corrected age and its association with adipose tissue metabolism biomarkers at birth (Aim 1) and to identify the role of early body composition assessments by magnetic resonance imaging and adipose tissue metabolism biomarkers at birth in predicting early childhood growth and development of adiposity and cardiometabolic abnormalities at age 2 years (Aim 2). Identification of these perinatal biomarkers is critical in the ability to risk-stratify infants at heightened risk of obesity and cardiometabolic abnormalities, and for the future development of interventions to optimize healthy growth and reduce obesity among preterm infants. Dr. Buck is a neonatologist whose long-term goal is to lead independent research examining perinatal risks that influence growth and development among preterm infants. The career development plan for this proposal builds upon Dr. Buck's prior training in epidemiology and clinical research methods through graduate-level coursework and mentored training in longitudinal study design, advanced biostatistical methods, biomarker and body composition assessment, and clinical trial study conduction. Dr. Buck has assembled a strong, committed team of mentors and advisors with expertise in infant nutrition, pediatric endocrinology, perinatal epidemiology, and biostatistics to help guide her successful transition to becoming an independent investigator, optimizing healthy growth and development of preterm infants and minimizing the development of obesity and cardiometabolic abnormalities in this vulnerable population.

项目概要 该研究项目的目的是确定脂肪组织发育指标和 新陈代谢是识别有儿童肥胖风险的早产儿的候选生物标志物 心脏代谢异常。中度早产、胎龄在 32 至 36 周之间的婴儿， 与足月出生的人相比，成年后患肥胖和心脏代谢疾病的几率高 20%。 中度早产占所有出生的 8%，即在美国出生的儿童大约有 300,000 名 每年各州。可能导致早产儿肥胖风险的因素包括发育障碍 由于围产期母亲肥胖和糖尿病的影响而制定的计划。初步数据表明 患有糖尿病的母亲所生的中度早产儿在平均 9 天的住院期间内生长速度更快 在调整胎龄、性别和种族后，与非糖尿病母亲的婴儿进行比较。加速 这些婴儿的生长可能是由于脂肪的发育、代谢和定位的改变 组织。在中度早产儿的前瞻性队列中，该项目的目标是： 母亲肥胖和妊娠糖尿病对足月校正年龄和肥胖发展的影响 它与出生时脂肪组织代谢生物标志物的关联（目标 1）并确定早期身体的作用 通过磁共振成像和出生时脂肪组织代谢生物标志物进行成分评估 预测儿童早期生长发育和 2 岁时肥胖和心脏代谢异常 年（目标 2）。这些围产期生物标志物的识别对于对婴儿进行风险分层的能力至关重要 肥胖和心脏代谢异常的风险增加，以及未来干预措施的发展 优化早产儿的健康成长并减少肥胖。 巴克博士是一位新生儿学家，其长期目标是领导检查围产期风险的独立研究 影响早产儿的生长发育。本提案的职业发展规划 建立在 Buck 博士之前通过研究生阶段接受的流行病学和临床研究方法培训的基础上 纵向研究设计、高级生物统计方法、生物标志物和 身体成分评估和临床试验研究的进行。巴克博士组建了一支强大、忠诚的团队 拥有婴儿营养、儿科内分泌学、围产期流行病学专业知识的导师和顾问团队， 和生物统计学来帮助指导她成功过渡到成为一名独立研究者，优化 早产儿的健康成长和发育，最大限度地减少肥胖和 这个弱势群体的心脏代谢异常。